Taurine exerts hypoglycemic effect in alloxan-induced diabetic rats, improves insulin-mediated glucose transport signaling pathway in heart and ameliorates cardiac oxidative stress and apoptosis

被引:104
作者
Das, Joydeep [1 ]
Vasan, Vandana [1 ]
Sil, Parames C. [1 ]
机构
[1] Bose Inst, Div Mol Med, Kolkata 700054, India
关键词
Akt; Alloxan-induced diabetes; Apoptosis; Cytokines; GLUT4; Heart; Hyperglycemia; Insulin receptor; Taurine; FACTOR-KAPPA-B; LIPID-PEROXIDATION; PROPHYLACTIC ROLE; NITRIC-OXIDE; ACTIVATION; PROTECTS; SERUM; CHOLESTEROL; METABOLISM; MELLITUS;
D O I
10.1016/j.taap.2011.11.009
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Hyperlipidemia, inflammation and altered antioxidant profiles are the usual complications in diabetes mellitus. In the present study, we investigated the therapeutic potential of taurine in diabetes associated cardiac complications using a rat model. Rats were made diabetic by alloxan (ALX) (single i.p. dose of 120 mg/kg body weight) and left untreated or treated with taurine (1% w/v, orally, in water) for three weeks either from the day of ALX exposure or after the onset of diabetes. Animals were euthanized after three weeks. ALX-induced diabetes decreased body weight, increased glucose level, decreased insulin content, enhanced the levels of cardiac damage markers and altered lipid profile in the plasma. Moreover, it increased oxidative stress (decreased antioxidant enzyme activities and GSH/GSSG ratio, increased xanthine oxidase enzyme activity, lipid peroxidation, protein carbonylation and ROS generation) and enhanced the proinflammatory cytokines levels, activity of myeloperoxidase and nuclear translocation of NF kappa B in the cardiac tissue of the experimental animals. Taurine treatment could, however, result to a decrease in the elevated blood glucose and proinflammatory cytokine levels, diabetes-evoked oxidative stress, lipid profiles and NF kappa B translocation. In addition, taurine increased GLUT 4 translocation to the cardiac membrane by enhanced phosphorylation of IR and IRS1 at tyrosine and Akt at serine residue in the heart. Results also suggest that taurine could protect cardiac tissue from ALX induced apoptosis via the regulation of Bcl2 family and caspase 9/3 proteins. Taken together, taurine supplementation in regular diet could play a beneficial role in regulating diabetes and its associated complications in the heart. (C) 2011 Elsevier Inc. All rights reserved.
引用
收藏
页码:296 / 308
页数:13
相关论文
共 91 条
[41]   Methods of detecting atherosclerosis in non-cardiac surgical patients; the role of biochemical markers [J].
Howard-Alpe, G. M. ;
Sear, J. W. ;
Foex, P. .
BRITISH JOURNAL OF ANAESTHESIA, 2006, 97 (06) :758-769
[42]   The effects of insulin and β-adrenergic stimulation on glucose transport, glut 4 and PKB activation in the myocardium of lean and obese non-insulin dependent diabetes mellitus rats [J].
Huisamen, B ;
van Zyl, M ;
Keyser, A ;
Lochner, A .
MOLECULAR AND CELLULAR BIOCHEMISTRY, 2001, 223 (1-2) :15-25
[43]   Doxorubicin treatment in vivo activates caspase-12 mediated cardiac apoptosis in both male and female rats [J].
Jang, YM ;
Kendaiah, S ;
Drew, B ;
Phillips, T ;
Selman, C ;
Julian, D ;
Leeuwenburgh, C .
FEBS LETTERS, 2004, 577 (03) :483-490
[44]   Azelnidipine protects myocardium in hyperglycemia-induced cardiac damage [J].
Kain, Vasundhara ;
Kumar, Sandeep ;
Puranik, Amrutesh S. ;
Sitasawad, Sandhya L. .
CARDIOVASCULAR DIABETOLOGY, 2010, 9
[45]   Effects of taurine in glucose and taurine administration [J].
Kaplan, B ;
Karabay, G ;
Zagyapan, RD ;
Özer, Ç ;
Sayan, H ;
Duyar, I .
AMINO ACIDS, 2004, 27 (3-4) :327-333
[46]  
Kim H, 2006, ADV EXP MED BIOL, V583, P137
[47]  
Kontny E, 2000, ARTHRITIS RHEUM, V43, P2169, DOI 10.1002/1529-0131(200010)43:10<2169::AID-ANR4>3.0.CO
[48]  
2-#
[49]   Attenuation of diabetic nephropathy by tocotrienol: Involvement of NFkB signaling pathway [J].
Kuhad, Anurag ;
Chopra, Kanwaljit .
LIFE SCIENCES, 2009, 84 (9-10) :296-301
[50]   HYPOGLYCEMIC PROPERTIES OF TAURINE - NOT MEDIATED BY ENHANCED INSULIN RELEASE [J].
KULAKOWSKI, EC ;
MATURO, J .
BIOCHEMICAL PHARMACOLOGY, 1984, 33 (18) :2835-2838